ERBB2 and non-small cell lung carcinoma: In a phase II basket trial, T-DM1 was administered at a dose of 3.6 mg/kg to 18 heavily pre-treated HER2-mutant patients with advanced NSCLC, achieving an ORR of 44% and a PFS of 5 months.